Impact of Thoracic Radiotherapy on First-Line Treatment Outcomes in ES-SCLC Patients

被引：0
|
作者：
Xiaoli, M. [1 ]
Yan, L. [2 ]
机构：
[1] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[2] Lung Canc Ctr, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Thoracic Radiotherapy; first-line immunotherapy and chemotherapy; extensive-stage small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.13D.08
引用
收藏
页码：S678 / S678
页数：1
相关论文
共 50 条
  • [31] Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Chemotherapy in ES-SCLC
    Reinmuth, Niels
    Paz-Ares, Luis
    Chen, Yuanbin
    Hotta, Katsuyuki
    Trukhin, Dmytro
    Statsenko, Galina
    Hochmair, Maximilian J.
    Ozguroglu, Mustafa
    Li, Jun Ho
    Voitko, Oleksandr
    Poltoratskiy, Artem
    Ponce, Santiago
    Verderame, Francesco
    Havel, Libor
    Bondarenko, Igor
    Kazarnowiczw, Andrzej
    Losonczy, Gyorgy
    Conev, Nicolay V.
    Armstrong, Jon
    Byrne, Natalie
    Shire, Norah
    Jiang, Haiyi
    Goldman, Jonathan
    Alt, Juergen
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 115 - 115
  • [32] Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
    Gao, F.
    Zhao, Y.
    Li, X.
    Li, Y.
    Ma, T.
    Li, Q.
    Tang, X.
    Han, X.
    Yi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1069 - S1069
  • [33] Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
    Bruni, A.
    Bertolini, F.
    Borghetti, P.
    Scotti, V.
    Sepulcri, M.
    Pasello, G.
    Giaj-Levra, N.
    Grisanti, S.
    Katica, M.
    Cappelli, A.
    Garlatti, P.
    Guaitoli, G.
    Dominici, M.
    Lohr, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S1068 - S1068
  • [34] The role of thoracic radiotherapy (TRT) in the era of chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC)
    Turner, Cassie L.
    Prasetio, Tito E.
    O'Berine, Shannon
    Anderson, Georgina
    Hughes, Brett G. M.
    Vignarajah, Dinesh
    Castelli, Joanne
    Lwin, Zarnie
    Houston, Kathleen
    Chan, Bryan A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 167 - 167
  • [35] First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes
    Schulz, C.
    Chen, Y.
    Paz-Ares, L. G.
    Dvorkin, M.
    Trukhin, D.
    Reinmuth, N.
    Garassino, M. C.
    Statsenko, G.
    Voitko, O.
    Hochmair, M. J.
    Ozguroglu, M.
    Verderame, F.
    Havel, L.
    Losonczy, G.
    Conev, N.
    Hotta, K.
    Ji, J. H.
    Broadhurst, H.
    Byrne, N.
    Thiyagarajah, P.
    Goldman, J. W.
    Alt, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 144 - 145
  • [36] Efficacy and safety of integrating consolidative thoracic radiotherapy with immunochemotherapy in ES-SCLC: A real-world retrospective analysis
    Zhang, Q.
    Liu, C.
    Wu, X.
    Zheng, C.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1069 - S1069
  • [37] Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China
    Zhou, Dongchu
    Dong, Xinrui
    Zhou, Zhen
    Liu, Qiao
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 2521 - 2529
  • [38] Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
    Daniel, D.
    Kuchava, V.
    Bondarenko, I.
    Ivashchuk, O.
    Spigel, D.
    Dasgupta, A.
    Reddy, S.
    Melkadze, T.
    Jaal, J.
    Kudaba, I.
    Hart, L.
    Matitashvili, A.
    Koynov, K. D.
    Yang, Z.
    Wolfe, S. G.
    Malik, R.
    Morris, S. R.
    Antal, J. M.
    Goldschmidt, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 713 - 713
  • [39] UPDATED PFS ANALYSIS OF TORIPALIMAB WITH ANLOTINIB AND CHEMOTHERAPY AS FIRST-LINE THERAPY IN PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC)
    Luo, Hao
    Jian, Dan
    Feng, Yan
    Zhong, Li
    Chen, Qian
    Guan, Wei
    Zhang, Shiheng
    Luo, Jiamin
    Yang, Xueqin
    Gong, Kan
    Xiong, Yanli
    Li, Mengxia
    Xu, Mingfang
    Pu, Yu
    Zhao, Liang
    Qian, Chengyuan
    Dai, Nan
    Wang, Dong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A490 - A490
  • [40] A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensivestage small cell lung cancer (ES-SCLC) patients
    Porte, M.
    Vaudron, A.
    Crequit, P.
    Chatellier, T.
    Fronteau, C.
    Raimbourg, J.
    Goronflot, T.
    Bennouna, J.
    Pons-Tostivint, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1068 - S1068
12345